They have recently reported impressive clinical outcomes with the use of a genetically mutated high-affinity TCR specific to NY-ESO-1 in the context of HLA-A*02:01, a representative cancer-testis antigen (CTA) that is overexpressed in various types of cancers, but negligibly expressed in almost all normal tissues except for testis [29]. This evidence concerns the gene HLA-A and cancer.